- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT07373444
Westlake Aging Cohort (WeAC)
Cohorte de Envelhecimento de Westlake
The Westlake Ageing Cohort (WeAC) is a longitudinal cohort study conducted in Hangzhou, Zhejiang Province, China. The investigators aim to enroll 2,800 participants aged 55 years and older for long-term follow-up. The population will include individuals with neurodegenerative diseases or those at the prodromal stage of cognitive impairment, as well as healthy middle-aged and older adults serving as controls. The investigators will collect their sociodemographic, dietary, lifestyle, clinical, and neuroimaging data, as well as biological samples.
Visão geral do estudo
Status
Descrição detalhada
The investigators will recruit middle-aged and aged participants, including healthy controls and individuals with neurodegenerative disorders such as mild cognitive impairment (MCI), Alzheimer's disease (AD), Parkinson's disease dementia (PDD), and dementia with Lewy bodies (DLB), etc. The aim of this study is to construct a longitudinal database that includes sociodemographic, lifestyle, clinical, neuroimaging, and multi-omics data. This database will be used to characterize the molecular signatures of neurodegenerative disorders. In addition, the investigators will identify biomarkers associated with neurodegenerative diseases. Furthermore, the investigators aim to uncover the mechanisms underlying the progression of mild cognitive impairment (MCI) and other neurodegenerative disorders.
Tipo de estudo
Inscrição (Estimado)
Contactos e Locais
Contato de estudo
- Nome: Ju-Sheng Zheng, PhD
- Número de telefone: 86-0571-86915303
- E-mail: zhengjusheng@westlake.edu.cn
Locais de estudo
-
-
Zhejiang
-
Hangzhou, Zhejiang, China, 310058
- Recrutamento
- Hangzhou First People's Hospital
-
Contato:
- Ju-Sheng Zheng, PhD
- Número de telefone: 86-0571-86915303
- E-mail: zhengjusheng@westlake.edu.cn
-
Hangzhou, Zhejiang, China, 310058
- Recrutamento
- Hangzhou Third People's Hospital
-
Contato:
- Peng Li, Master
-
Contato:
- Yu Chen, Master
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Método de amostragem
População do estudo
All participants must be Chinese residents, regardless of their ethnicity.
Descrição
Inclusion Criteria:
- Age between 55 and 90 years (inclusive) at baseline.
- Availability of a companion capable of providing independent functional assessments and fluent in Chinese.
- Willingness and ability to regularly complete required surveys and physical examinations as per study protocol.
- MMSE scores were required to be 24-30 (inclusive) for healthy controls and MCI; and 20-24 (inclusive) for AD and DLB/PDD patients.
- Healthy controls: CDR = 0, memory box = 0. MCI: CDR = 0.5, memory box ≥ 0.5. AD: CDR = 0.5 or 1. The DLB/PDD meets the core features of diagnosis.
- Healthy controls exhibit no significant cognitive or functional decline. Patients with MCI have objective cognitive impairment not sufficient for an AD diagnosis. AD patients fulfill the NINCDS-ADRDA criteria. DLB/PDD patients meet their respective international consensus diagnostic criteria. Other neurodegenerative diseases meet the diagnostic criteria.
Exclusion Criteria:
- Participants with major medical or neuropsychiatric conditions unrelated to the study purposes were excluded. These included, but were not limited to, psychiatric disorders, cancer, infectious diseases, structural brain abnormalities, and epilepsy.
- Current use of psychoactive medications or any other drugs that may affect the study.
- Participants with cardiac pacemakers, artificial heart valves, or metallic implants in the eyes, skin, or any other part of the body.
- Participants with any other diseases that may affect the study.
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Modelos de observação: COHORT
- Perspectivas de Tempo: PROSPECTIVE
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Cognitive function
Prazo: 48 months
|
Cognitive function will be evaluated using the Mini-Mental State Examination (MMSE, score range: 0-30, with higher scores indicating better cognitive function) and clinical diagnosis provided by physicians. |
48 months
|
|
Gut microbiome
Prazo: 48 months
|
The gut microbiome will be profiled by metagenomic sequencing or ITS rRNA sequencing. In addition, fecal microbiota will be cultured, isolated, and identified. |
48 months
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Brain magnetic resonance imaging
Prazo: 48 months
|
Use brain magnetic resonance imaging (MRI) to measure the brain structure and function of participants. |
48 months
|
|
Positron emission tomography
Prazo: 48 months
|
Assess the brain function and neurological disorders by positron emission tomography (PET). |
48 months
|
|
Brain images relevant inspections
Prazo: 48 months
|
Other brain image relevant inspections required for study to measure brain structure and function of participants. |
48 months
|
|
Electroencephalogram
Prazo: 48 months
|
Electroencephalogram (EEG) monitors the electrical activity of the brain. And further measure based on coupled EEG/MEG and eye-tracking. |
48 months
|
|
Blood biochemical parameters
Prazo: 48 months
|
Blood biochemical parameters, including glucose and lipids, will be analyzed using an automated biochemical analyzer. |
48 months
|
|
Serum inflammatory factors
Prazo: 48 months
|
Detect and assess serum inflammatory factors such as IL-1β, IL-6, and IL-12, in serum from participants. |
48 months
|
|
Health and behavior monitoring
Prazo: 48 months
|
Use fitness trackers to record the physiological and behavioral data of participants. |
48 months
|
|
Sleep data measurement
Prazo: 48 months
|
Use the polysomnography (PSG) to record the sleep data of participants to evaluate the sleep quality. |
48 months
|
|
Continuous glucose monitoring
Prazo: 48 months
|
Use the continuous glucose monitoring (CGM) for dynamic blood glucose recording to determine the glycemic control of participants. |
48 months
|
|
Environmental measurement
Prazo: 48 months
|
Use the environmental monitoring device to measure various exposure factors in the participants' living environment. |
48 months
|
|
Multi-omics data
Prazo: 48 months
|
Multi omics results of detecting biological samples such as plasma, peripheral blood mononuclear cells (PBMCs), urine, feces, saliva, etc. |
48 months
|
Colaboradores e Investigadores
Patrocinador
Colaboradores
Investigadores
- Investigador principal: Ju-Sheng Zheng, PhD, Westlake University
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Conclusão Primária (Estimado)
Conclusão do estudo (Estimado)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
- 20251023ZJS001
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .